FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/07/070528 [Registered on: 12/07/2024] Trial Registered Prospectively
Last Modified On: 11/07/2024
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Unani
Diagnostic 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   A Study On Qooba (Tinea Pedis) With Unani Medicine Habbe Kibreet Sagheer And Dimad (local application) A Unani Formulation. 
Scientific Title of Study   Efficacy Of Habbe Kibreet Sagheer And Dimad In Comparison With Itraconazole and Clotrimazole in Tinea Pedis- A Randomized Open Labelled Control Clinical Trial  
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  SHAIKH MOHAMMAD AATIF AFZAL 
Designation  PG SCHOLAR 
Affiliation  National Institute Of Unani Medicine  
Address  Dept of Amraze Jild Wa Tazeeniyat National Institute of Unani Medicine Kottigepalya Magadi main road Banglore 560091 karnataka India

Bangalore
KARNATAKA
560091
India 
Phone  9028786215  
Fax    
Email  aatifshaikh1234@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr. Mohd Arshad Jamal  
Designation  Associate Professor  
Affiliation  National Institute Of Unani Medicine  
Address  Department Of Amraze Jild Wa Tazeeniyat National Institute Of Unani Medicine Kottigepalya Magadi Main Road Bangalore 560091 Karnataka India

Bangalore
KARNATAKA
560091
India 
Phone  7767993333  
Fax    
Email  sarimnium@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Prof Mohd Aleemuddin Quamri 
Designation  HOD Amraze Jild Wa Tzeeniyat & Moalajat (i/c) 
Affiliation  National Institute Of Unani Medicine  
Address  Dept of Amraze Jild Wa Tazeeniyat National Institute of Unani Medicine Kottigepalya Magadi main road Banglore 560091 karnataka India


KARNATAKA
560091
India 
Phone  9341072974  
Fax    
Email  drmaquamri@gmail.com  
 
Source of Monetary or Material Support  
National Institute Of Unani Medicine Kottegepalya Magadi Main Road Bangalore 560091 Karnataka India  
 
Primary Sponsor  
Name  National Institute Of Unani medicine 
Address  Department of Amraze Jild Wa Tazeeniyat National institute of Unani Medicine Kottigepalya Magadi main road banglore 560091 Karnataka 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr SHAIKH MOHAMMAD AATIF AFZAL  National Institute Of Unani Medicine Kottigepalya Magadi Main Road Banglore 560091 Karnataka India  Amraze Jild Wa Tazeeniyat OPD/IPD NIUM Hospital Bangalore
Bangalore
KARNATAKA 
9028786215

aatifshaikh1234@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee (IEC) For Biomedical Research  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: B353||Tinea pedis,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  habb Kibreet and zimaad  Habbe Kibreet Sagheer and Zimad in Comparison with Itraconazole and clotrimazole in Tinea Pedis.Habbe kibreet sagheer 500 mg BD will be administrated orally (after meal) for 4 weeks and Zimad will be applied to the affected lesion Locally twice a day for 4 weeks. 
Comparator Agent  Tablet Itraconazole and Ointment Clotrimazole  Itraconazole 100mg tab and clotrimazole 1% cream. Itraconazole 100mg tablet BD for 4 weeks with clotrimazole 1% cream should be applied on the affected area 2 times every day for 4 weeks. 
 
Inclusion Criteria  
Age From  15.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  1.Clinically and microscopically diagnosed patient of Tinea Pedis

2.Subjects of all genders

3.Age group 15-60 years

4.Subjects who have agreed to sign the informed consent form

5.All four types of Tinea Pedis include
 
 
ExclusionCriteria 
Details  1.Subjects below 15 years and 60 years of age

2.Pregnant and lactating women

3.Subjects with a history of systemic and metabolic disorder

4.Subject with a history of uncontrolled Diabetes, HIV/AIDS, or Immunocompromised patient

5.Subjects with concomitant skin diseases like eczema, psoriasis, and onychomycosis
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Pharmacy-controlled Randomization 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
1)Negative KOH scraping
2)Change in photography of lesions

 
0th (baseline),7th Day,14th Day, 21st Day,28th Day,35th Day. 
 
Secondary Outcome  
Outcome  TimePoints 
• Decrease in TSS  0th (baseline),7th Day,14th Day 21st Day,28th Day,35th Day 
 
Target Sample Size   Total Sample Size="40"
Sample Size from India="40" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2/ Phase 3 
Date of First Enrollment (India)   22/07/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Need of the study:

Tinea pedis, also known as athlete’s foot, is dermatophytosis of the feet, the most common fungal infection.1 The prevalence of tinea pedis increases with age,2 and it is higher in males than females.3 It affects at least 10% of the world’s population at any given time. Males are infected at about three Times more often than females.4 This is probably due to habitual and occupational differences between genders. Women participate less often in sports activities and they wear open shoes more often than males. Moreover, women devote more time to foot hygiene than men.5 Common causes of tinea pedis include T. rubrum, Trichophyton interdigitale, and Epidermophyton floccosum. Direct contact with the causative organism is the usual method of infection, which may occur through barefoot, contact between the feet and an infected surface in locker rooms and swimming pools. In the winter, the use of occlusive footwear is more common, and this leads to increased incidences of tinea pedis. Tinea pedis is more frequent in athletes and blue-collar workers.

In the conventional structure of medicine, the treatment of dermatophyte infection usually implies azole, imidazole, or allylamine derivatives in various dosage forms. Common drugs used are Fluconazole, Itraconazole, Griseofulvin, and Terbinafine, etc.6 Mild cases respond well to topical treatment, such as topical terbinafine, Ciclopirox, and econazole. severe cases and cases in which topical treatment has failed require systemic treatment, as one-third of tinea pedis cases failed to respond to topical therapy. In recent years we have seen a notable rise in the incidence of chronic dermatophyte infections which have proven strenuous to treat.7 In conventional systems of medicine, the identification of drugs that selectively kill or inhibit fungi but are not toxic to human cells has been highly complicated.8 Besides, some other factors like drug resistance, adverse drug reactions, recurrency, and chronicity of the disease are the obstacles. Problems with antifungal drugs and the emergence of more fungal species have created a heavy demand for new antifungal drugs.

In Unani medicine, tinea pedis is not defined separately, however, Unani physicians have described ‘QOOBA’ as a broader term that also includes Tinea pedis. Unani medicines possess the desired properties with widely varied dosage formulations that can cure tinea pedis, but these formulations are not scientifically evaluated. Hence there is a need to evaluate these preparations clinically and validate the efficacy/claim of Unani drugs mentioned in classical Unani literature which have been indicated and tested for centuries. Unani System of medicines has enormous potential in this field and a lot more work must be done. Therefore, the present study entitled “Efficacy of Ḥabbe Kibreet Sagheer and Ḍimād in Comparison with Itraconazole and clotrimazole in Tinea Pedis- A Randomized Open Labelled Control Clinical Trial” has been designed to validate and to provide effective management of Tinea Pedis.

 

 

Review of Literature:

Dermatophytoses are fungal infections caused by three genera of fungi that can invade and multiply within keratinized tissue (hair, skin, and nails). These fungi collectively called “dermatophytes”, are alike in their physiology, morphology, and pathogenicity. The three genera are Microsporum, Trichophyton, and Epidermophyton; these genera that do not invade keratinized tissue in animals or humans are not considered dermatophytes.  The term “tinea” precedes the Latin name for the involved body site, e.g. “tinea pedis” refers to dermatophyte infection of the foot.9

 

Tinea pedis is also known as a “Ringworm of the foot” and “Athlete’s foot”. Tinea pedis is a dermatophyte infection of the soles and interdigital web spaces of the feet. This condition is more common in adults than children and is found around the world, affecting both sexes. The lack of sebaceous glands and the moist environment created by occlusive shoes are important factors in the development of the tinea pedis. In fact, tinea pedis is uncommon in populations that do not wear shoes. However, the fungus may be acquired from going barefoot (locker rooms, gyms, public facilities).

The dermatophytes that are typically responsible for tinea pedis are T. rubrum (Most common) T. interdigitale (Previously T. mentagrophytes var. Interdigitale), T. mentagrophytes, E. floccosum, and T. tonsurans (in children).9

Types of Tinea pedis:10

 Tinea pedis may present as any of four forms, or combinations thereof 

 

1. Interdigital type (Athlete’s foot): The most common presentation of tinea pedis begins as scaling, erythema, and maceration of the interdigital and sub-digital skin of the feet, particularly between the lateral 3rd and 4th and 4th and 5th toes.

 

2. Chronic hyperkeratotic (Moccasin) type: In chronic hyperkeratotic type tinea pedis, there is patchy or diffuse scaling on the soles and the lateral and medial aspect of the feet, in a distribution like a moccasin on a foot.

 

3. Vesiculobullous type: It is typically caused by zoophilic strains of T. interdigitale (former T. mentagrophytes var. mentagrophytes), features tense vesicles larger than 3mm in diameter, vesiculobullous pustules and bullae on the soles and periplantar areas.

 

4. Acute ulcerative type: It is zoophilic T. interdigitale along with rampant bacterial superinfection with gram -ve organisms produces vesicles, pustules, and purulent ulcers on the plantar surface.

 

According to the Unani system of medicine, Qooba is a type of roughness that is produced under the skin and causes itching. Sometimes it appears blackish and sometimes reddish in color.11 According to Ahmad bin Tabri ‘the cause of Qooba is Ghaleez Akhlāṭ especially Ghaleez Ḍam and Ghaleez Sawda’.11 It is due to sanguine (Ḍamvi) humour which is burnt and transformed into morbid melancholic humour.12 It is produced by Mirrah Sawdaʼ.13

The basic principles of management of Qooba include Tadeele Mizaj, Tanqiya mawad (Evacuation of morbid material) and Taskīn wa Tabrīd. The regimental therapy includes Faṣd (Venesection), Ḥammām (Bath), and Taʻlīq al-ʻAlaq(Leech therapy). Faṣd (Venesection) and drugs for evacuation for Khilṭ-e-sawdaʼ (Melancholic humour) should be used. Those drugs with Muḥallil, mulaṭṭif, musakkin, muṣaffī, muʻaddil, and muraṭṭib properties are to be used. Gandhak Maghsool, Filfil siyah, Namak Hindi, Aab-e-Leemu, etc. have the above-mentioned properties.11,14

Objectives of the study:

To evaluate the comparative efficacy of “Ḥabbe Kibreet Sagheer and Ḍimād with Itraconazole and Clotrimazole in Tinea Pedis.



 
Close